Roche's enicepatide meets both Phase II primary endpoints in type 2 diabetes and obesity trial

Roche reported positive Phase II results for its drug enicepatide in patients with type 2 diabetes and overweight or obesity, saying it met both primary endpoints. The trial showed reductions in blood-sugar levels and weight.

Detected & updated continuously · Source: Nebula